Rapamycin for Cats Shows Promise in Preventing Feline Heart Disease (HCM)
A potential breakthrough in feline medicine is offering new hope to cat owners and veterinarians battling hypertrophic cardiomyopathy (HCM), a leading cause of sudden death in cats. The drug rapamycin, long studied for its anti-aging properties in humans and animals, is now showing strong potential as rapamycin for cats, building on broader longevity research discussed in Can rapamycin really help you live longer? and Is rapamycin an effective longevity drug?.
A Historic Milestone: FDA Approval of Felicyn-CA1
On March 14, the U.S. Food and Drug Administration (FDA) granted conditional approval for felicyn-CA1, a delayed-release formulation of rapamycin (also known as sirolimus), for use in cats with subclinical HCM, a stage of cat heart disease before outward symptoms appear. This approval reflects growing confidence in rapamycin’s role across species, including recent findings in rapamycin for pets and longevity.
The decision follows compelling research led by Joshua Stern, DVM, PhD, DACVIM (Cardiology), associate dean at North Carolina State University. Stern’s study demonstrated that rapamycin can slow or reverse the thickening of the heart muscle—the hallmark of HCM—an effect linked to its regulation of the mTOR pathway, explored in depth in Rapamycin and mTOR: the hidden switch controlling aging.
“For years, veterinarians could only monitor HCM and hope for the best,” said Stern. “Now, we may finally have a proactive tool to fight back.”
What Is Rapamycin?
Originally discovered in 1972, rapamycin was first noted for its antimicrobial effects. It was later recognized for its immune-modulating and anti-tumor properties, and more recently for influencing the mTOR pathway, which is closely tied to aging, metabolism, and cellular repair. These mechanisms are central to modern longevity science and are discussed further in What’s next for rapamycin in longevity research.
Its use in cats is now being explored not only for cardiac protection but also within the broader context of rapamycin treatment for cats, mirroring findings from aging and healthspan studies in other mammals.
The HALT Study: Next Steps in Research
Stern is now leading a larger follow-up trial, HALT (Hypertrophic cardiomyopathy And siroLimus Trial), which aims to enroll hundreds of cats to further assess the long-term effects of rapamycin for cats with subclinical HCM. Similar translational research approaches have already shown promise in dogs, as highlighted in Can rapamycin slow aging in dogs?.
Cats must meet criteria such as:
- Elevated proBNP (a heart enzyme)
- Echocardiographic evidence of subclinical HCM
General practitioners can easily test for proBNP and refer eligible patients, helping expand access to advanced cat heart disease treatment.
A Cautious but Hopeful Outlook
Veterinary cardiologist Courtney Smith, DVM, MS, DACVIM, who is involved with the HALT study in Los Angeles, sees promise but urges caution.
“We’re still early in this journey,” Smith said. “There’s no long-term data yet. But if rapamycin holds up under further study, it could change the way we manage cat heart disease.”
Similar cautious optimism has surrounded rapamycin’s effects in other conditions, including inflammation and metabolic health, as discussed in Rapamycin and the future of healthy aging and Rapamycin heart health study.
Looking Ahead
According to TriviumVet, the Ireland-based manufacturer of felicyn-CA1, the drug could be available to veterinarians by summer 2025. In the meantime, HALT is actively enrolling, and veterinarians can visit the study website to find participation criteria, register patients, and locate study sites.
For cat lovers and clinicians alike, rapamycin for cats may represent the first real hope in the fight against feline HCM—a condition that, until now, left too many questions and too few answers—while reinforcing rapamycin’s expanding role across longevity science, from pets to humans, as explored in Rapamycin and longevity science.
